Q1 Adjusted EPS of $2.05 Crushes Estimates, ANI Pharmaceuticals Raises Full-Year Guidance
ANIP sits 56% above its 52-week low of $56.71.
Summary
ANI Pharmaceuticals reported robust first-quarter results, significantly exceeding analyst expectations for both adjusted EPS and revenue. The company posted adjusted EPS of $2.05, well above the IBES estimate of $1.30, and revenue of $237.5 million, surpassing the $207.6 million estimate. Furthermore, ANI Pharmaceuticals raised its full-year adjusted EPS, revenue, and EBITDA guidance, with the new outlook exceeding current IBES estimates. This strong performance and optimistic forward guidance signal continued operational strength and positive momentum, building on the financial rebound seen in 2025, and is likely to be viewed very positively by the market.
At the time of this announcement, ANIP was trading at $88.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $56.71 to $99.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.